Continue current treatment and monitor results through the second half of 2026 TRIUMPH-2 data will clarify whether a switch in 2028 makes clinical sense for your situation
Retatrutide: How the Triple Agonist Compares to Tirzepatide Quick Answer Retatrutide is a synthetic 26-amino acid peptide that simultaneously activates three receptor pathways: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors
Pernicious anemia occurs more commonly in people who already have diseases that are linked to immune-system abnormalities, such as Graves disease, hypothyroidism (under-functioning thyroid gland), thyroiditis (inflammation of the thyroid), vitiligo, and Addison's disease (adrenocortical insufficiency)
In matched-duration trial comparisons, retatrutide has shown greater average body weight reduction than tirzepatide, though no completed head-to-head Phase 3 trial exists yet
doi: 10.1111/dom.14286 23 CarusoICignarelliAGiorginoF
If it stays cloudy or has visible bits after a few minutes, set it aside and contact your supplier rather than injecting it
